-
Company Insights
Innovation and Patenting activity of Vivo Energy Plc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Vivo Energy Plc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dilanubicel in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dilanubicel in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dilanubicel in Acute Lymphocytic Leukemia (ALL,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dilanubicel in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dilanubicel in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dilanubicel in Chronic Myelocytic Leukemia (CML,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Exagamglogene Autotemcel in Sickle Cell Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Exagamglogene Autotemcel in Sickle Cell Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Exagamglogene Autotemcel in Sickle Cell Disease Drug Details: Exagamglogene autotemcel...
-
Sector Analysis
Brazil Telecom Operators Country Intelligence Report
Brazil Telecom Operators Country Intelligence Overview The total telecom and pay-TV service revenue in Brazil reached $29.3 billion in 2022. The market size has been estimated to grow at a CAGR of more than 4% during 2022-2027, primarily driven by increasing demand for mobile and fixed broadband connectivity. The growth is also attributed to National broadband Initiative aimed at deploying fiber-optic high-capacity networks for data transmission and internet access in the country, along with regulator and telco initiatives to expand...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Cellular Immunotherapy For Hepatocellular Carcinoma And Non-Small Cell Lung Cancer in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cellular Immunotherapy For Hepatocellular Carcinoma And Non-Small Cell Lung Cancer in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cellular...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – IMCY-0141 in Relapsing Remitting Multiple Sclerosis (RRMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMCY-0141 in Relapsing Remitting Multiple Sclerosis (RRMS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMCY-0141 in Relapsing Remitting Multiple Sclerosis (RRMS) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SMART-101 in Myelodysplastic Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SMART-101 in Myelodysplastic Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SMART-101 in Myelodysplastic Syndrome Drug Details: SMART-101 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – FPT-155 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FPT-155 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FPT-155 in Triple-Negative Breast Cancer (TNBC) Drug Details: FPT-155 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SMART-101 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SMART-101 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SMART-101 in Acute Myelocytic Leukemia (AML, Acute...